US Pharma MarketingThe post Senseonics begins first human trial of Freedom CGM appeared first on Medical Device Network.
Senseonics begins first human trial of Freedom CGM
Senseonics Holdings has begun a first-in-human clinical study to assess Freedom, its investigational CGM system. Senseonics intends to use the resulting safety data and findings to guide a pivotal trial planned for 2027. Senseonics currently markets Eversense 365, a long-term CGM system featuring a healthcare-provider-inserted sensor and a removable smart transmitter. Credit: Gecko Studio / Shutterstock.com. Medical technology company Senseonics Holdings has begun a first-in-human clinical study to assess Freedom, its investigational continuous glucose monitoring (CGM) system. The device is designed to transmit data directly to a mobile handset without requiring an external on-body transmitter. Combine business intelligence and editorial…
Senseonics Holdings has begun a first-in-human clinical study to assess Freedom, its investigational CGM system.
Source: Medical Device Network